JP2021532071A5 - - Google Patents

Info

Publication number
JP2021532071A5
JP2021532071A5 JP2020572381A JP2020572381A JP2021532071A5 JP 2021532071 A5 JP2021532071 A5 JP 2021532071A5 JP 2020572381 A JP2020572381 A JP 2020572381A JP 2020572381 A JP2020572381 A JP 2020572381A JP 2021532071 A5 JP2021532071 A5 JP 2021532071A5
Authority
JP
Japan
Prior art keywords
approximately
composition according
aav
polysorbate
sodium chloride
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020572381A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021532071A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/041398 external-priority patent/WO2020014479A1/en
Publication of JP2021532071A publication Critical patent/JP2021532071A/ja
Publication of JP2021532071A5 publication Critical patent/JP2021532071A5/ja
Pending legal-status Critical Current

Links

JP2020572381A 2018-07-11 2019-07-11 Ａａｖ組成物 Pending JP2021532071A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862696792P 2018-07-11 2018-07-11
US62/696,792 2018-07-11
PCT/US2019/041398 WO2020014479A1 (en) 2018-07-11 2019-07-11 Aav compositions

Publications (2)

Publication Number Publication Date
JP2021532071A JP2021532071A (ja) 2021-11-25
JP2021532071A5 true JP2021532071A5 (https=) 2022-07-19

Family

ID=69142590

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020572381A Pending JP2021532071A (ja) 2018-07-11 2019-07-11 Ａａｖ組成物

Country Status (13)

Country Link
US (1) US12553062B2 (https=)
EP (1) EP3820490A4 (https=)
JP (1) JP2021532071A (https=)
KR (1) KR20210032984A (https=)
CN (1) CN112469427A (https=)
AU (1) AU2019299964A1 (https=)
BR (1) BR112021000327A2 (https=)
CA (1) CA3104196A1 (https=)
CO (1) CO2020016147A2 (https=)
IL (1) IL279537A (https=)
MX (1) MX2020013953A (https=)
SG (1) SG11202012946RA (https=)
WO (1) WO2020014479A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012018628A1 (en) 2010-07-26 2012-02-09 Board Of Regents, The University Of Texas System Methods for inducing an immune response via buccal and/or sublingual administration of a vaccine
US9974850B2 (en) 2013-01-25 2018-05-22 Board Of Regents, The University Of Texas System Immunogenic compositions and uses thereof
EP3510161A4 (en) 2016-08-23 2020-04-22 Akouos, Inc. COMPOSITIONS AND METHODS FOR TREATING PERSONAL HEARING LOSS IN A PERSON
KR20220157944A (ko) 2020-02-21 2022-11-29 아카우오스, 인크. 인간 대상체에서 비-연령-연관 청각 장애를 치료하기 위한 조성물 및 방법
AU2021265768B2 (en) * 2020-04-27 2023-03-30 4D Molecular Therapeutics Inc. Adeno-associated variants, formulations and methods for pulmonary delivery
WO2022236008A1 (en) * 2021-05-07 2022-11-10 Board Of Regents, The University Of Texas System Methods and compositions for transport, storage, and delivery of adeno-associated viral vector and other molecules
CN117980471A (zh) 2021-08-04 2024-05-03 武田药品工业株式会社 阳离子交换剂上的腺相关病毒分离
US20230090654A1 (en) * 2021-08-24 2023-03-23 Homology Medicines, Inc. Adeno-associated virus formulations
CN116350801A (zh) * 2022-11-22 2023-06-30 四川至善唯新生物科技有限公司 一种重组腺相关病毒载体的药物组合物及其用途
WO2025076729A1 (zh) * 2023-10-11 2025-04-17 朗信启昇(苏州)生物制药有限公司 包含aav的药物组合物及其制备方法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8801338D0 (en) 1988-01-21 1988-02-17 Quadrant Bioresources Ltd Preservation of viruses
EP0728195A1 (en) 1993-10-12 1996-08-28 Chiron Corporation Methods for preserving recombinant viruses
PT1061955E (pt) 1998-03-13 2005-08-31 Wyeth Corp Composicao de polinucleotido, metodo de preparacao e sua utilizacao
US6759050B1 (en) 1998-12-03 2004-07-06 Avigen, Inc. Excipients for use in adeno-associated virus pharmaceutical formulations, and pharmaceutical formulations made therewith
JP5118798B2 (ja) 2000-03-07 2013-01-16 メルク・シャープ・エンド・ドーム・コーポレイション アデノウイルス製剤
US20030153065A1 (en) 2002-01-14 2003-08-14 Genvec, Inc. Composition and method for maintaining non-enveloped viral vectors
BRPI0511764B8 (pt) 2004-06-01 2021-05-25 Avigen Inc método de prevenção de agregação de vírions de vírus adeno-associado recombinante (raav) em uma preparação purificada de virions raav
CA2722238C (en) 2008-04-22 2017-11-28 Life Sciences Research Partners Vzw Liver-specific nucleic acid regulatory elements and methods and use thereof
PL4218797T3 (pl) * 2009-09-21 2025-02-10 Takeda Pharmaceutical Company Limited Stabilizowane płynne i liofilizowane preparaty adamts13
IT1405793B1 (it) 2010-10-15 2014-01-24 Univ Ferrara Molecola di u1snrna umano modificato, gene codificante per la molecola di u1snrna umano modificato, vettore di espressione includente il gene, e loro uso in terapia genica
EP2646051A4 (en) * 2010-12-02 2014-05-28 Oncolytics Biotech Inc FORMULATIONS OF LIQUID VIRUSES
MX349294B (es) 2010-12-02 2017-07-21 Oncolytics Biotech Inc Formulaciones virales liofilizadas.
WO2013036961A1 (en) 2011-09-09 2013-03-14 Api Genesis Llc A pain relief composition, comprising a trpv1 selective agonist, and manufacture and uses thereof
US10093947B2 (en) 2012-02-28 2018-10-09 Cornell University AAV-directed persistent expression of an anti-nicotine antibody gene for smoking cessation
US9254332B2 (en) 2013-03-15 2016-02-09 Arecor Limited Stable aqueous formulations of adenovirus vectors
WO2015040234A1 (en) * 2013-09-23 2015-03-26 Crucell Holland B.V. Adenovirus formulations
GB201403684D0 (en) 2014-03-03 2014-04-16 King S College London Vector
WO2016004319A1 (en) 2014-07-02 2016-01-07 University Of Florida Research Foundation, Inc. Compositions and methods for purifying recombinant adeno-associated virus
WO2016154055A1 (en) 2015-03-20 2016-09-29 Bluebird Bio, Inc. Vector formulations
EP3384015A4 (en) * 2015-12-01 2019-05-29 Spark Therapeutics, Inc. SCALABLE PROCESS FOR THE PREPARATION OF A RECOMBINANT ADENO ASSOCIATED VIRAL VECTOR IN A SERUM-FREE SUSPENSION CELL CULTURE SYSTEM SUITABLE FOR THE CLINICAL APPLICATION
BR112019009113A2 (pt) * 2016-11-04 2019-07-16 Baxalta Incorporated formulações de vírus adenoassociado
CA3040288A1 (en) * 2016-11-04 2018-07-12 Baxalta Incorporated Adeno-associated virus purification methods
JP2021505610A (ja) * 2017-12-05 2021-02-18 アプライド ジェネティック テクノロジーズ コーポレイション ウイルス粒子のための製剤最適化
EP3731863A4 (en) * 2017-12-29 2021-10-27 Baxalta Incorporated ADENO-ASSOCIATED VIRUS CLEANSING PROCEDURES

Similar Documents

Publication Publication Date Title
JP2021532071A5 (https=)
JP2019537578A5 (https=)
RU2019116442A (ru) Составы с аденоассоциированным вирусом
JP2022529002A5 (https=)
JP2025128087A5 (https=)
TWI756185B (zh) 腺相關病毒因子viii載體、相關病毒粒子及包含其之治療調配物
JP4879104B2 (ja) 高度に濃縮された、凍結乾燥された、および液体の、因子ｉｘ処方
TW202103718A (zh) 腺相關病毒載體調配物及方法
JP2025509566A5 (https=)
JP2021523198A (ja) 幼若対象におけるａａｖベクターの安定的発現
JP2022547197A5 (https=)
US20230293724A1 (en) Lyophilized Formulations of AAV Drug Products
KR20230122076A (ko) 아데노-연관 바이러스 벡터를 함유하는 개선된 제약조성물
US20240307553A1 (en) Pharmaceutical compositions containing adeno-associated viral vector
Keravala et al. 316. Evaluating AAV Hybrid Variants for Improved Tropism after Intravitreal Gene Delivery to the Retina
KR20210153069A (ko) 섬유아세포 성장 인자 23 관련 저인산혈증성 질환의 유전자 요법
JP2022521840A5 (https=)
CN115337408A (zh) 腺相关病毒制剂
CN117180455A (zh) 腺相关病毒药物组合物及其用途
RU2020142674A (ru) Композиции AAV
US20240240204A1 (en) Methods and compositions for transport, storage, and delivery of adeno-associated viral vector and other molecules
WO2026030714A1 (en) Pharmaceutical compositions containing blood brain barrier penetrant aav capsids
CN117298296A (zh) 一种重组腺相关病毒x载体制剂
RU2022106918A (ru) Составы с аденоассоциированным вирусом
RU2815545C2 (ru) Генная терапия гипофосфатемических заболеваний, связанных с фактором роста фибробластов 23